Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).
RATIONALE-305 (NCT03777657) is a randomized, double-blind, placebo-controlled, global Phase 3 trial comparing the efficacy and safety of tislelizumab combined with platinum and fluoropyrimidine chemotherapy to placebo combined with platinum and fluoropyrimidine chemotherapy as a first-line treatment for patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
This factsheet describes the final analysis of the Phase 3 RATIONALE-305 trial, where tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intention-to-treat (ITT) population compared to chemotherapy alone. The safety profile of tislelizumab plus chemotherapy was manageable in patients with unresectable, locally advanced or metastatic GC/GEJC. No new safety signals were identified.
The RATIONALE-307, RATIONALE-304, and RATIONALE-303 trials were designed to evaluate the safety and efficacy of tislelizumab as a monotherapy and in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC).
Download this factsheet to review the study design and key efficacy and safety takeaways.
Reading
